SRT 2104

Drug Profile

SRT 2104

Alternative Names: GSK-2245840; SRT-2104

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sirtris
  • Developer GlaxoSmithKline
  • Class Antihyperglycaemics; Antipsoriatics; Small molecules
  • Mechanism of Action SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders; Chronic obstructive pulmonary disease; Inflammation; Muscular atrophy; Plaque psoriasis; Type 2 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 28 Feb 2013 Sirtris completes a phase Ib trial in Ulcerative colitis in the US (NCT01453491)
  • 01 Dec 2012 Sirtris completes a phase I trial (in volunteers) in Plaque psoriasis in USA (NCT01702493)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top